Insider Buying: Vivani Medical (NASDAQ:VANI) Director Purchases $1,999,999.48 in Stock

Vivani Medical, Inc. (NASDAQ:VANI) Director Gregg Williams bought 1,351,351 shares of the stock in a transaction that occurred on Tuesday, January 27th. The shares were purchased at an average price of $1.48 per share, for a total transaction of $1,999,999.48. Following the completion of the acquisition, the director owned 27,915,460 shares of the company’s stock, valued at $41,314,880.80. The trade was a 5.09% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Gregg Williams also recently made the following trade(s):

• On Thursday, January 15th, Gregg Williams acquired 1,737,765 shares of Vivani Medical stock. The stock was purchased at an average cost of $1.14 per share, with a total value of $1,981,052.10.
• On Monday, December 15th, Gregg Williams acquired 1,737,765 shares of Vivani Medical stock. The shares were purchased at an average price of $1.14 per share, for a total transaction of $1,981,052.10.
• On Saturday, November 15th, Gregg Williams bought 1,737,764 shares of Vivani Medical stock. The stock was purchased at an average price of $1.14 per share, with a total value of $1,981,050.96.

Vivani Medical Stock Performance

Vivani Medical stock opened at $1.39 on Friday. The stock has a 50-day simple moving average of $1.35 and a 200 day simple moving average of $1.40. The stock has a market capitalization of $108.66 million, a P/E ratio of -3.09 and a beta of 3.07. Vivani Medical, Inc. has a 52 week low of $0.91 and a 52 week high of $1.92.

Vivani Medical (NASDAQ:VANI) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.01. Research analysts forecast that Vivani Medical, Inc. will post -0.41 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on VANI shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Vivani Medical in a research report on Friday, January 9th. Wall Street Zen raised shares of Vivani Medical to a “sell” rating in a report on Saturday, November 22nd. Finally, Zacks Research upgraded Vivani Medical from a “strong sell” rating to a “hold” rating in a report on Wednesday, November 12th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $4.00.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Panagora Asset Management Inc. acquired a new stake in shares of Vivani Medical in the second quarter valued at approximately $25,000. Citadel Advisors LLC bought a new position in Vivani Medical during the 3rd quarter worth $26,000. Finally, Susquehanna International Group LLP raised its holdings in Vivani Medical by 100.5% in the 3rd quarter. Susquehanna International Group LLP now owns 32,314 shares of the company’s stock valued at $46,000 after acquiring an additional 16,200 shares in the last quarter. 6.78% of the stock is owned by institutional investors.

Vivani Medical Company Profile

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.